Journal of Neuro-Oncology

, Volume 97, Issue 1, pp 53–57 | Cite as

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy

  • Lorenzo Falchi
  • Marco Gunnellini
  • Laura Franco
  • Patrizia Ferrazza
  • Stefano Ascani
  • Anna Marina Liberati
Clinical Study - Patient Study


Prognosis of patients suffering from secondary central nervous system (CNS) lymphoma is dismal. Intracranial spread of a lymphoma arising in adjacent extranodal tissues is a rare event. A 32-year-old patient was diagnosed with progressive diffuse large B-cell lymphoma (DLBCL) with extra- and intracranial localization. He complained of headache, left diplopia, marked rigidity of the neck muscles, and difficulty in swallowing and articulating words, caused by bilateral palsy of the XII cranial nerve. Computed tomography (CT) and positron emission tomography (PET) scans showed disease localizations in the occipital-cervical soft tissue, and cerebellar parenchyma. Due to the severity of the clinical picture, high-dose dexamethasone was immediately administered. Mild improvement was observed during the first 2 days of treatment, but dramatic reduction of symptoms and nerve palsy was documented only in the 48 h after the first intrathecal administration of liposomal Ara-C. Systemic R-MegaCEOP chemotherapy was started 7 days later. Concomitant intrathecal liposomal Ara-C injections were continued for a total of nine administrations during the eight cycles of immunochemotherapy without any toxicity observed. Interim and post-therapy PET showed complete resolution of radionuclide accumulation in the involved sites. Consolidation radiotherapy (36 Gy) was administered in involved areas after the completion of the immunochemotherapy program. At the time of writing, no cumulative neurotoxicity is evident at follow-up of 17 months from diagnosis and 9 months after the overall therapeutic program has been accomplished.


Diffuse large B-cell lymphoma Intrathecal therapy Lyposomal Ara-C R-MegaCEOP 


  1. 1.
    Salzburg J, Burkhardt B, Zimmermann M et al (2007) Prevalence, clinical pattern and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype. A Berlin-Frankfurt-Munster Group Report. J Clin Oncol 25:3915–3922CrossRefPubMedGoogle Scholar
  2. 2.
    Van Besien K, Ha CS, Murphy S et al (1998) Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate grade and immunoblastic lymphoma. Blood 91:1178–1184PubMedGoogle Scholar
  3. 3.
    Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 11:685–690CrossRefPubMedGoogle Scholar
  4. 4.
    Hollender A, Kvaloy S, Lote K et al (2000) Prognostic factors in 140 adult patients with non-Hodgkin’s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36:1762–1768CrossRefPubMedGoogle Scholar
  5. 5.
    Keldsen N, Michalski W, Bentzen SM et al (1998) Risk factors for central nervous system involvement in non-Hodgkin-lymphoma: a multivariate analysis. Acta Oncol 35:703–708CrossRefGoogle Scholar
  6. 6.
    McMillan A (2005) Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 131:13–21CrossRefPubMedGoogle Scholar
  7. 7.
    Jahnke K, Thiel E, Martus P et al (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85:45–50CrossRefPubMedGoogle Scholar
  8. 8.
    Hollender A, Kvaloy S, Nome O et al (2002) Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 13:1099–1107CrossRefPubMedGoogle Scholar
  9. 9.
    Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18:149–157CrossRefPubMedGoogle Scholar
  10. 10.
    Kasamon YL, Jones RJ, Piantadosi S et al (2005) High dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 11:93–100CrossRefPubMedGoogle Scholar
  11. 11.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288CrossRefPubMedGoogle Scholar
  12. 12.
    Graham FL, Whitmore GF (1970) The effect of 1-beta-d-arabinofuranosyl-cytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 30:2627–2635PubMedGoogle Scholar
  13. 13.
    Pels H, Schulz H, Schlegel U et al (2003) Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26:351–354CrossRefPubMedGoogle Scholar
  14. 14.
    Rubenstein JL, Combs D, Rosenberg J et al (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466–468CrossRefPubMedGoogle Scholar
  15. 15.
    Bekassy AN, Liliemark J, Garwicz S et al (1990) Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. Med Pediatr Oncol 18:136–142CrossRefPubMedGoogle Scholar
  16. 16.
    Gleissner B, Chamberlain M (2007) Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 84:107–117CrossRefPubMedGoogle Scholar
  17. 17.
    Kwong Y-L, Yeung DYM, Chan JCW (2009) Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 88:193–201CrossRefPubMedGoogle Scholar
  18. 18.
    Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301–309CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Lorenzo Falchi
    • 1
  • Marco Gunnellini
    • 1
  • Laura Franco
    • 1
  • Patrizia Ferrazza
    • 1
  • Stefano Ascani
    • 2
  • Anna Marina Liberati
    • 1
  1. 1.Institute of Oncohematology – AutotransplantationUniversity of Perugia, Santa Maria HospitalTerniItaly
  2. 2.Institute of Pathologic AnatomyUniversity of Perugia, Santa Maria HospitalTerniItaly

Personalised recommendations